Another clinical trial study in 2018 tested the combination therapy of ruxolitinib and the BCR::ABL inhibitor nilotinib in CML patients, resulting in positive outcomes which warranted progress to the next phase [244]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.